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~ T h e  of Chest Pain: Interatlve Management 
Lessons  F rom a Chest  Pain Center  
R J. Sternal. R. Grant, K. Eagle. Bolsford Gonor, ql Hospital and Untv of 
M¢I~ Ho~trt Cam Oufconlo~ Asses,~ment Te~lm. USA 
To asse~s impa0t of n chest pain center (CPC) end patient management 
algorithm (PMA) on resource use and outcomes for chest pain (CP) patients 
(pt,) evaluated at n community I~ospltnl, we studied pie presenting 1o our 
Emergency Dopnrtment (EU) from 1093-1996. In 1993 we established a 
CPC. In mid,1995, we established a CP PMA using AHCPR Unstable Angina 
Guidelines directing intermediate risk pie to the CPC rather than edmission 
(admit) to hospital, We tracked ED. CPO and Hospital edmlt, and 0,month 
and 1,yssr o~,ltcomas of CPC pie following eroatioo of PMA, PMA was 
operatlonnlitsd truing a roseamh based 0rltlcal pnlhway, legal physi0inn 
partiolpatlon, a local clinical ohamplon, nnd feedback, 
Rest#Ill: CPC Increased CP edmtt from 591 of 2.200 ED visits in t993 to 
an av9, of 050 of 2,400 ED visits in mid,1005. +0%, After PMA. admit dropped 
in 1999 to 470 of 2,250 ED oontagts, -20% (ovorafl p ,  0,001), Short slay 
admits to CPC increased Item 19 in 1993. to 347 In 1999. +17~6%. Among 
473 pts 1rooked nt 0 and 1~ monlhs nftor CPC dtscl~srge from mid.95 through 
199fi, ~ wero "intermediate risk", 466 undenN~nt stress tasting (ST), 13 
h~d (,) ST, sad 4 had CABG or PTC~, 11 pie sought rare dunng follow.up 
and a~lsr ( , )  slr0ss tOM; 3 reqtllrort CAB.G, 1 had a non.QMI, No pt died 
following dlsl.'~harga tram CPC with a favorable evaluation in CPC. 
Conch~Slon: Creation el n CPC alone lad to increased admit rates tot CP 
of 9%, Creation of a PMA led to a ~9% rodu¢l~on in admit, pamoulally among 
tnlormedtalo ask pts, One yea1 follow.tip fol nearly $00 pts suggests PMA 
can he ante y~l effective in Idnntlfyin9 high ask pie for admit and lower risk 
pie lot dischsrgn. 
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Introduction, The purpose of this study was to compare patient outcome be- 
tween high, modtllm nnd low riFk UA patlnnt~, detinnd by the AHCPR guideline 
to similar risk groups defined by a validated modal t~m our institution (JAMA 
19951 I:~sed on Brm.mwalrt cntona (prolonged pain, ST depression, post MI. 
medication, age and diabetes). Four hundred sixteen patients oonsocutively 
admitted with UA patients between January 1, 1995 and Juno 30. 1997 wore 
prospectively evaluated for major events (+) (ML death or heart tadure). 
Real#Is 
RUSH AHCPR 
Low Medium H~h Low Medium High 
Eve*~t t ~ I",,I le2 (gt! 231192l 53190t ~'1 t951 269 (931 1041921 
Event l* I l%) 3t31 20tS~ 6(101 1 (5~ 19(7! SiS) 
IV Ntg, n [%) 10 ttSI 119 t4T) 43 t73) S (36) 113 140J 58 (511 
Hop~nn, n (%! 7S t74! ~n8 tsJ) 49 (83) 20 (at) 218 (78) 98 (871 
Sa~e w, n ~'%t 8 tRI 31 (1~) 10 (IT) 2 (91 37 t131 10 t9) 
Neither model differentiates well between medium and high risk patients 
but both models do Identity patients with low event rates. However, the Rush 
model allowed for 5 times more patients to be candidates for outpatient evalu- 
ation (low nsk) with significantly lower obsowod event rotes than the AHCPR 
model (p ,  0.0011; also, the Rush model more successlully predicts the use 
of IV nitroglycerin and coronary surgery, We concluded the Rush model can 
be used clinically to identify patients for eady noninvasivn evaluation, thereby 
~mpmving cost effectiveness of care. 
E I ~  Implementat ion  of  a Computer i zed  
Card iovescu ls r  In format ion System In a Pr ivate 
Hospital Set t ing  
G.S, Taylor, J,B, Muhlestein, G.S. Wagner, T,L Bait. P. Li, J. Anderson, 
Unive~ity ot c,','ah. LDS Hospital, Salt Lake Ci~. UT; Duke Universi~ 
Durham, NO, U,.~A 
B~ckgmund: Utilizing clinical databases has been shown to be helpful in 
improwng quality of care, reducing operating costs, securing managed care 
contracts, and assisting in clinical research Because much physic,an input 
is required to maintain these systems, private institutions have often found 
them difficult to implement. At LDS Hospital. we developed a cardiovascular 
information system (LDS-CIS) designed for ease of use in a private hospital 
setting. 
Methods: Features of the system include concise single-page report 
forms, a relational database allowing for queries of all data tields, auto- 
matic generation of final procedure reports, and electronic merging of all 
data with the hospital's information system. Data from more than 15,000 
patients have been entered, 
Results" LDS-CIS provides easy access 1o data for research 1o improve 
patient care, Using dsta generated by LDS-ClS, the policy requiong surgical 
backup during PTCA was eliminated, rosultln9 in no incrsnso In patient risk 
while saving needy $1,000,000 in1 year, LDS,CIS generates physioian feed- 
beck reports, documenting Individual performance compared 1o pears, This 
physioian self-evaluation has homogenized and improved cam In,gradation 
from LDS.CIS has boon instrumental in securing and maintaining managed 
rare P, nntregte, LDS.CIS ask analysis provides physicians with outoomea 
dat~ specifio to their current patient's demographina and level 01 disease 10 
assist in point.or-gate decisions, 
Conclusion: The use el LDS,CIS in the routine operations el LOS Hospaal 
heart sen/ices is feasibl0, beneficial, and coM.efleotiw. 
~ H o w  Revaecularhmtlon Chosen In Is Therapy  
Pat ients With Mu l t lvaeee l  O laMIo?  
A.D. Rosen. P Guo. K. Detm. AE. SiewQrs. R.J Shomin. MM Brooks. 
T.J. VandotSalm. E,L, Alderman Untve~iPV of P~ff~bufgh. P~lts~Jrgh. F~4. 
USA 
BARi malntalns a rogisilV el 2010 mUglVOSSel disease patients eligible for 
both PTCA and CABG who declined randomlzatioo. CABG was the mmal 
prooedum for 35% nf 1781 registn/patients undergoing one el these pmoB- 
dures . 3 months after onrellment. Logistic rogmssloo was used to tdentdy 
lndopondonl predictors tar CABG Ewcept for angina status, a poor tO tat, 
self-rating 01 health and smoking, other clinical factors (Hx 01 MI, CHF, dis. 
betas, hVPertenslon, age, gender, education) were not p ~  el CABG 
The likelihood el CASG increased in patients with angmgrsph¢c tealure~ 
such as proximal LAD lesions, numerous ,50% lesions, and with chnK:alty 
relevant lesions iaappropoato tor PTCA; the likelihood of CABG ~sed 
when lesions would not or could not be bypassed. Except for the latter, 
angiographic predictors of CABG were not associated with total or ca~ae 
mortality, adjusted for besoltno nsk factors. Although the chore ot CABG ts 
often assumed 1o indicate a high ask patient, those angmgraphK: features 
worn not prognostic el 5 yr mortahfy in BARI patients. 
Patient Undergo CAEIG vs PICA Cmckac Mortality, 
Charoctertstl¢ Odds Raho t95% Ct) Relatp.'e Risk 195% Cti 
Proximal LAD lesion .50% 1 76 (1 4:2-2 20) 0 84 tO ,53-1 33l 
3 Vessel Disease (vs 2) I 71 (1 34-2 181 1 50 tO 97-2 31) 
4+ Lesions -50% 1 44 (1 11-1 06) 1 14 in 69-: s91 
lecomptete PTCA score t 1 7211 35-;? 19l 0 aT to 5,.3-1 4.5) 
Incomplete CABG 2 0 41 tO 27 ~ 62'1 2 03 t t 14-3 6Oi 
t ScOred aS :2 = would not dilate a culprit lesion 50%. t ; WOUh~ nOt chl,~te a cb~=iC<lihl 
important lesion . 50%. O = othoP.vlso: 2Would not b¥~ss a, Ios~ons 50% 
~ Economic of Statins: Price Versus Segmentation 
Efficiency 
J.D. Miller t , D.M Huso t . M W. Russell 1 , P. Sarocco:, S.C. Hartz ~ . '~.~hcal 
Research Intematronal. Burhngton, MA, USA. :Parks-Davis. Morr,s Plains. 
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Background: The emergence ol HMG-CoA-reductase inhibitors i'storms') as 
staples in the treatment ot hypethpldemia is due to their suponor efficacy 
and toterability relative to other classes o1 lipid regulators. Paredoxtcalty. 
however, two of the three most recent members of this class (tluvastatm 
and cerivastatin) are less effective in Iowenng LDL levels than previously 
marketed statins, and am being priced and promoted as "economy" brands. 
Methods: To evaluate these claims, we used a decision-analytic model 
of the clinical and economic consequences o! lipid regulating therapy to 
compare the cost-effectiveness o1 16 fixed-dose statin regimens, For ator- 
vastatin, fluvastatin, tovastatin, pravastatin, and simvastatin we estimated 
efficacy based on U.S. product labeling and daily cost based on pubhshed 
U.S. wholesale acquisition coat. For cenvastatin, efficacy was based on 
published trials and daily cost was based on current UK paces tU,S la- 
beling and price were not yet published). The model generated estimates ot 
net cost (lipid regulating therapy minus savings in treatment el CHD) and 
eflectivenes- (CHD risk reSuction) o1 each therapy. 
Results: Atorvastatin provides greater risk reduction at less cost than 
simvastatin, pravastatin, and Iovastatin. while cerwastatin exhibits similar 
superionty to fluvastatin. Compared to cerivastatin, atorvastatin provides 
increased risk reduction at increased cost. 
Conclusion: Cerivastatin is the most economical stalin only if the desired 
CHD risk reduction does not exceed 16-.-28% (i.e,. for high-risk men and 
low-risk women, respectively) over 5 years, If greater clinical benefit is sought, 
atorvastatin is the most efficient therapeutic option. 
